Press release
Human Immunodeficiency Virus Type 1 (HIV-1) Market is expected to reach USD 44.7 billion by 2034
Human Immunodeficiency Virus Type
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71725
The HIV-1 market continues to evolve, driven by innovation in long-acting therapies, two-drug regimens, and global initiatives to expand testing and treatment access. With pipeline research exploring vaccines, broadly neutralizing antibodies (bNAbs), and potential cures, the next decade promises both growth and disruption.
Market Overview
• Market Size (2024): USD 28.4 billion
• Forecast (2034): USD 44.7 billion
• CAGR (2025-2034): 4.6%
The market remains robust, fueled by rising HIV prevalence in low- and middle-income countries, expanded global ART programs, and innovation in long-acting injectable treatments.
Key Highlights:
• Over 39 million people globally live with HIV, with HIV-1 accounting for ~95% of cases.
• ART has transformed HIV-1 into a manageable chronic condition.
• FDA and EMA approvals of long-acting injectables (cabotegravir/rilpivirine) mark a paradigm shift.
• Strong research in vaccines, cure strategies, and bNAbs.
Segmentation Analysis
By Product Type:
• Antiretroviral Therapy (ART)
o Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
o Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
o Protease Inhibitors (PIs)
o Integrase Strand Transfer Inhibitors (INSTIs)
o Entry Inhibitors (CCR5 antagonists, fusion inhibitors)
• Long-Acting Injectables
o Cabotegravir + Rilpivirine (Cabenuva)
o Lenacapavir (pipeline)
• Pre-Exposure Prophylaxis (PrEP)
o Tenofovir/Emtricitabine (Truvada, Descovy)
o Long-acting PrEP (cabotegravir)
• Pipeline Therapies
o Vaccines (mRNA-based, viral vector)
o Broadly Neutralizing Antibodies (bNAbs)
o Gene Editing & Cure Research
By Platform:
• Small Molecules
• Biologics
• Gene Therapy Research
By Technology:
• Antiviral Drug Development Platforms
• Long-Acting Injectable Delivery Systems
• Vaccine and bNAb Engineering
• AI-Based Drug Discovery
By End Use:
• Hospitals
• Specialty Infectious Disease Clinics
• Research Institutes
• Home Care (self-administered ART, telehealth)
By Application:
• Treatment of HIV-1 Infection
• Prevention (PrEP)
• Clinical Research for Cure & Vaccines
Segmentation Summary:
ART dominates the market, but long-acting injectables and PrEP are reshaping prevention and adherence strategies. Pipeline innovations in vaccines and bNAbs represent the most disruptive future opportunity.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71725/human-immunodeficiency-virus-type-1-hiv-1-market
Regional Analysis
North America
• Largest market with ~44% share in 2024.
• Strong ART adoption and early launch of long-acting injectables.
• Robust R&D ecosystem with ongoing vaccine trials.
Europe
• Holds ~30% share.
• Germany, UK, and France lead in adoption of new regimens.
• EMA-approved PrEP expansion improving prevention strategies.
Asia-Pacific
• Fastest-growing region with CAGR of ~6.0%.
• High HIV prevalence in India, China, and Southeast Asia.
• Expanding ART access through government and NGO programs.
Middle East & Africa
• Highest disease burden but limited access to advanced therapies.
• Global aid programs (PEPFAR, Global Fund) expanding ART coverage.
Latin America
• Brazil and Mexico lead in ART coverage and PrEP adoption.
• Increasing role of government-funded HIV initiatives.
Regional Summary:
North America and Europe dominate in innovation and early adoption, while Asia-Pacific grows fastest due to expanding ART coverage. Africa remains a major focus for global aid-driven HIV care expansion.
Market Dynamics
Key Growth Drivers:
• Rising global HIV-1 prevalence.
• Expanding ART and PrEP adoption.
• Long-acting injectables improving adherence.
• Strong vaccine and cure research pipelines.
Key Challenges:
• High cost of new therapies in low-income regions.
• Stigma and underdiagnosis in many parts of the world.
• Drug resistance with long-term ART use.
• Complex logistics of ART access in rural/remote areas.
Latest Trends:
• Approval of Cabenuva, the first long-acting injectable ART regimen.
• mRNA-based HIV vaccine research inspired by COVID-19 vaccine success.
• bNAbs showing promise for prevention and functional cure.
• Digital adherence monitoring and telehealth integration.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71725
Competitor Analysis
Major Players in the Market:
• Gilead Sciences, Inc. (Biktarvy, Descovy, Truvada)
• ViiV Healthcare (GSK + Pfizer + Shionogi) (Cabenuva, Triumeq, Dovato)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Merck & Co., Inc. (Isentress, Doravirine)
• Roche Holding AG
• Moderna, Inc. (mRNA-based HIV vaccine pipeline)
• BioNTech SE (vaccine development)
• AbbVie Inc.
• Cipla Ltd. (generic ART leadership)
• Lupin Limited
Competitive Summary:
Gilead and ViiV Healthcare dominate the ART and PrEP markets, while J&J and Merck remain strong in integrase and NNRTI segments. Moderna and BioNTech are advancing HIV vaccines. Generics players like Cipla and Lupin provide affordable ART access globally.
Conclusion
The HIV-1 Market, valued at USD 28.4 billion in 2024, is projected to reach USD 44.7 billion by 2034, growing at a CAGR of 4.6%. Expanding ART access, innovation in long-acting injectables, and strong vaccine and cure pipelines will continue to shape the global HIV landscape.
Key Takeaways:
• ART remains the backbone of treatment, but injectables are the biggest innovation.
• North America and Europe dominate in innovation, while Asia-Pacific grows fastest.
• Africa remains the highest-need region, supported by global aid.
• Vaccines, bNAbs, and gene editing hold future curative potential.
The next decade will redefine HIV-1 management, transitioning from lifelong oral therapy to long-acting injectables, preventive vaccines, and functional cure research, creating opportunities for pharma innovators and healthcare providers.
This report is also available in the following languages : Japanese (ヒト免疫不全ウイルス1型(HIV-1)市場), Korean (인간 면역 결핍 바이러스 1형(HIV-1) 시장), Chinese (人类免疫缺陷病毒 1 型(HIV-1)市场), French (Marché du virus de l'immunodéficience humaine de type 1 (VIH-1)), German (Markt für das humane Immundefizienzvirus Typ 1 (HIV-1)), and Italian (Mercato del virus dell'immunodeficienza umana di tipo 1 (HIV-1)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71725/human-immunodeficiency-virus-type-1-hiv-1-market#request-a-sample
Our More Reports:
X-Linked Retinitis Pigmentosa Market
https://exactitudeconsultancy.com/reports/72282/x-linked-retinitis-pigmentosa-market
X-Linked Retinoschisis Market
https://exactitudeconsultancy.com/reports/72283/x-linked-retinoschisis-market
Fuchs Endothelial Corneal Dystrophy (FECD) -Market Insights, Epidemiology, and Market
https://exactitudeconsultancy.com/reports/72284/fuchs-endothelial-corneal-dystrophy-fecd-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Immunodeficiency Virus Type 1 (HIV-1) Market is expected to reach USD 44.7 billion by 2034 here
News-ID: 4177324 • Views: …
More Releases from Exactitude Consultancy
Genital Herpes Market is expected to double, reaching USD 5.8 billion by 2034
Genital herpes is a chronic, sexually transmitted viral infection caused primarily by the herpes simplex virus type 2 (HSV-2), and in some cases by HSV-1. The condition is characterized by painful genital sores, recurrent outbreaks, and psychological distress. While not life-threatening, genital herpes remains a major public health issue due to its high global prevalence, risk of vertical transmission during childbirth, and role in increasing susceptibility to HIV.
Download Full PDF…
Catheter-Related Bloodstream Infection (CRBSI) Market is expected to reach USD 3 …
Catheter-related bloodstream infections (CRBSIs) are among the most serious and common hospital-acquired infections, caused when pathogens enter the bloodstream through central venous catheters (CVCs), peripherally inserted central catheters (PICCs), or other intravascular devices. These infections significantly increase patient morbidity, hospital stays, and healthcare costs, making their prevention and treatment a top priority in modern healthcare.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71721
The market for CRBSI is expanding due…
Neurofibroma Market to Reach USD 1.1 Billion by 2034
The global Neurofibroma Market is experiencing steady momentum, driven by increasing prevalence of neurofibromatosis, advancements in molecular diagnostics, and rising research funding for rare genetic disorders. As a benign nerve sheath tumor with potential to transform into malignant forms in some cases, neurofibroma represents a unique therapeutic challenge. The industry is evolving through new treatment modalities, robust diagnostic frameworks, and targeted therapies that are expanding patient access worldwide.
Download Full PDF…
Molybdenum Cofactor Deficiency Type A (MoCD-A) Market New Product Development & …
Introduction
Molybdenum Cofactor Deficiency Type A (MoCD-A) is a rare, life-threatening metabolic disorder that presents significant clinical challenges due to its early onset, rapid progression, and limited therapeutic options. Though the condition is ultra-rare, awareness, early diagnosis, and emerging targeted therapies are shaping a growing market opportunity. Over the next decade, pharmaceutical innovation, rising rare disease research funding, and improved newborn screening programs are expected to significantly influence the MoCD-A treatment…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
